. Author manuscript; available in PMC: 2021 Sep 1.

Published in final edited form as: Clin Lung Cancer. 2020 Apr 13;21(5):421–427.e2. doi: 10.1016/j.cllc.2020.04.003

Table 2.

Regimens utilized prior to immunotherapy.

Regimens^*	Patients, N (% of total population)
Alkylating agents¹ and Antimetabolites²	794 (25.1%)
Alkylating agents	565 (17.9%)
Alkylating agents and Taxanes³	351 (11.1%)
Alkylating agents and Topoisomerase inhibitors⁴	278 (8.8%)

Full list of agents and their corresponding codes are listed in the Supplemental Materials

^1.

Alkylating agents include carboplatin, cisplatin, oxaliplatin, cyclophosphamide

^2.

Antimetabolites include gemcitabine, pemetrexed

^3.

Taxanes include docetaxel, paclitaxel

^4.

Topoisomerase inhibitors include topotecan, irinotecan